DX-126262 is under clinical development by Hangzhou DAC Biotech and currently in Phase I for Breast Cancer. According to GlobalData, Phase I drugs for Breast Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DX-126262’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DX-126262 is under development for the treatment of HER2-positive or HER2-mutated unresectable locally advanced or metastatic non-squamous NSCLC, HER2 positive breast cancer, breast cancer, adenocarcinoma of the gastroesophageal junction, gastric cancer, advanced or recurrent metastatic urothelial carcinoma, bladder cancer, ureter cancer, renal pelvis cancer and urethral cancer. The drug candidate is an antibody drug conjugate comprising recombinant humanized anti-Her2 monoclonal antibody conjugated to Tub-114. It is formulated as lyophilized powder and administered via intravenous route of administration.
Hangzhou DAC Biotech overview
Hangzhou DAC Biotech Co. Ltd., a biopharmaceutical company and focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drugs. The company is headquartered China.
For a complete picture of DX-126262’s drug-specific PTSR and LoA scores, buy the report here.